Edition:
United States

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.23USD
25 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.23
Open
$2.24
Day's High
$2.27
Day's Low
$2.16
Volume
9,228
Avg. Vol
42,285
52-wk High
$2.71
52-wk Low
$1.00

Chart for

About

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary... (more)

Overall

Beta: --
Market Cap(Mil.): $129.67
Shares Outstanding(Mil.): 55.18
Dividend: --
Yield (%): --

Financials

  BLPH.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -1.37 -- --
ROI: -207.10 -0.73 12.97
ROE: -712.01 -2.77 14.84

BRIEF-Bellerophon Q4 Loss Per Share $0.44

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Bellerophon Says Over 100 Patients In Late-Stage Study Testing Inopulse For Treatment Of High Blood Pressure

* BELLEROPHON THERAPEUTICS ANNOUNCES ENROLLMENT EXCEEDS 100 PATIENTS IN PHASE 3 INOVATION-1 STUDY EVALUATING INOPULSE® FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

Jan 29 2018

BRIEF-Bellerophon Says First Patient Enrolled In Phase 2B Study Evaluating Inopulse For Treating Pulmonary Hypertension

* BELLEROPHON-FIRST PATIENT ENROLLED IN PHASE 2B STUDY EVALUATING INOPULSE FOR TREATING PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE

Jan 03 2018

BRIEF-Bellerophon Appoints Ted Wang To Its Board Of Directors

* BELLEROPHON APPOINTS TED WANG, PH.D., OF PUISSANCE CAPITAL MANAGEMENT, TO ITS BOARD OF DIRECTORS

Nov 30 2017

BRIEF-Bellerophon Therapeutics reports Q3 loss per share $0.22

* Bellerophon provides business update and reports third quarter 2017 financial results

Nov 07 2017

Earnings vs. Estimates